)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Scancell Holdings
Scancell Holdings (SCLP) investor relations material
Scancell Holdings H2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H2 2026 earnings summary9 Oct, 2026
Executive summary
Advanced melanoma Phase 3 trial of iSCIB1+ planned for Q4 2026, following FDA IND clearance and fast track designation and UK MHRA authorization.
Proposed Neuphoria merger and related financing could fund development plans, but completion depends on shareholder, regulatory and other conditions.
Financial highlights
FY2026 revenue was £nil vs £4.7m in FY2025; R&D expenses fell to £12.0m from £14.7m, mainly due to lower manufacturing costs.
Operating loss widened to £17.4m from £15.0m; net loss was £17.9m vs £12.3m, with no £1.8m convertible-note modification gain recorded in FY2026.
Cash and cash equivalents were £5.3m at 30 April 2026 vs £16.9m a year earlier; net cash used in operating activities was £10.8m.
Outlook and guidance
Phase 3 iSCIB1+ trial targeting ~550 patients with unresectable Stage IIIB or IV melanoma is expected to start in Q4 2026; further Phase 2 SCOPE PFS data expected in H1 2027.
A randomized neoadjuvant/adjuvant iSCIB1+ Phase 2 trial is intended for H1 2027, subject to financing and regulatory clearance.
Further ModiFY data for HNSCC and RCC are expected later in 2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Scancell Holdings
- iSCIB1+ shows strong efficacy in advanced melanoma, with phase III and commercial expansion underway.SCLP
H.C. Wainwright 28th Annual Global Investment Conference - iSCIB1+ delivers robust efficacy in melanoma with a defined path to approval and major market potential.SCLPCorporate presentation
- Strong clinical progress and partnerships set up multiple value drivers and milestones for 2025.SCLPInvestor update
- SCOPE study advances with strong early results as GlyMab spinout drives strategic momentum.SCLPStatus update
- iSCIB1+ plus checkpoint inhibitors achieved 69% response and 69% PFS at 22 months in melanoma.SCLPStudy update
- iSCIB1+ achieved 74% PFS at 16 months, surpassing standard care and supporting phase III plans.SCLPStudy update
- Lead cancer vaccines deliver strong interim results; cash runway secured to H2 2026.SCLPH1 2025
- iSCIB1+ shows robust melanoma efficacy, supporting pipeline growth and solid cash runway.SCLPH2 2025
- iSCIB1+ achieved 74% PFS in melanoma; Phase 3 trial and key data readouts expected in 2026.SCLPH1 2026
Next Scancell Holdings earnings date
H1 202728 Jan, 2027
Scancell Holdings
Next Scancell Holdings earnings date
H1 202728 Jan, 2027
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage